Evonik Upgrades Contract Manufacturing CapabilitiesEvonik Upgrades Contract Manufacturing Capabilities
September 20, 2018

Specialty chemicals producer Evonik announced the recent completion of a €36 million (about $42 million) project to expand its contract manufacturing capabilities for APIs and advanced intermediates at the firm’s facilities in the U.S. and Europe, a press release said Wednesday.
Within the last year, the German firm introduced a number of new technologies at several of its production sites, including systems for continuous processing, mPEGs, fermentation, and high-potency API (HPAPI).
“Our mission is to help our customers bring to market innovative molecules with complex manufacturing processes, and in this context, global scale, expertise, and flexibility matter,” Dr. Jean-Luc Herbeaux, senior vice president and head of the Evonik Health Care business line, said in a statement. “Evonik will continue to be a leader in advanced technologies that make the industrialization and commercialization of these highly specialized products possible.”
The company recently commissioned a new modular cGMP continuous processing facility at its location in Hanau, Germany, as well as a pilot plant for custom made highly pure PEGs and mPEGs for use in pharmaceuticals. Evonik also opened a cGMP suite for small-scale production of HPAPI and ultra-HPAPI in Hanau.
Evonik also increased the footprint and added capabilities to its facilities in Hanau and in Tippecanoe, IN to support the small, medium, or large-scale production of HPAPI. An investment was made in a facility in Slovakia to open a new, flexible pilot plant for downstream processing.
“Advanced technologies will continue to be deployed across our global network in response to emerging customer needs. In parallel, our commitment to quality and regulatory excellence will continue to drive all business activities,” Dr. Andreas Meudt, vice president and head of Exclusive Synthesis at Evonik, said in the release. “The fact that our Tippecanoe facility in the U.S. has now recorded six consecutive FDA inspections without a Form 483 is an indication of how we can provide customers with peace-of-mind.”
For more news headlines, articles, and equipment reviews, visit our Equipment Zones
You May Also Like